These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22806140)

  • 1. INDI: a computational framework for inferring drug interactions and their associated recommendations.
    Gottlieb A; Stein GY; Oron Y; Ruppin E; Sharan R
    Mol Syst Biol; 2012 Jul; 8():592. PubMed ID: 22806140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
    Iga K; Kiriyama A
    J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
    Ohno Y; Hisaka A; Ueno M; Suzuki H
    Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive-Unlabeled Learning for inferring drug interactions based on heterogeneous attributes.
    Hameed PN; Verspoor K; Kusljic S; Halgamuge S
    BMC Bioinformatics; 2017 Mar; 18(1):140. PubMed ID: 28249566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
    Preskorn SH
    J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.
    Gabriel L; Tod M; Goutelle S
    Clin Pharmacokinet; 2016 Aug; 55(8):977-90. PubMed ID: 26936044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties.
    Cheng F; Zhao Z
    J Am Med Inform Assoc; 2014 Oct; 21(e2):e278-86. PubMed ID: 24644270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-drug interaction discovery and demystification using Semantic Web technologies.
    Noor A; Assiri A; Ayvaz S; Clark C; Dumontier M
    J Am Med Inform Assoc; 2017 May; 24(3):556-564. PubMed ID: 28031284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches.
    Grime K; Ferguson DD; Riley RJ
    Curr Drug Metab; 2010 Dec; 11(10):870-85. PubMed ID: 21208171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
    Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.